On Friday, Ocular Therapeutix Inc (NASDAQ: OCUL) opened lower -7.44% from the last session, before settling in for the closing price of $8.87. Price fluctuations for OCUL have ranged from $3.76 to $11.77 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 123.40% annually for the last half of the decade. Company’s average yearly earnings per share was noted -16.86% at the time writing. With a float of $135.64 million, this company’s outstanding shares have now reached $156.65 million.
In an organization with 267 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 90.58%, operating margin of -230.12%, and the pretax margin is -284.02%.
Ocular Therapeutix Inc (OCUL) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Ocular Therapeutix Inc is 13.72%, while institutional ownership is 77.42%. The most recent insider transaction that took place on Nov 25 ’24, was worth 26,561. In this transaction Chief Scientific Officer of this company sold 2,948 shares at a rate of $9.01, taking the stock ownership to the 269,059 shares. Before that another transaction happened on Nov 25 ’24, when Company’s Chief Development Officer sold 2,897 for $9.01, making the entire transaction worth $26,102. This insider now owns 213,087 shares in total.
Ocular Therapeutix Inc (OCUL) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.25 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -16.86% per share during the next fiscal year.
Ocular Therapeutix Inc (NASDAQ: OCUL) Trading Performance Indicators
Check out the current performance indicators for Ocular Therapeutix Inc (OCUL). In the past quarter, the stock posted a quick ratio of 12.94. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 21.01.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.32, a number that is poised to hit -0.25 in the next quarter and is forecasted to reach -1.07 in one year’s time.
Technical Analysis of Ocular Therapeutix Inc (OCUL)
Let’s dig in a bit further. During the last 5-days, its volume was 0.82 million. That was better than the volume of 0.8 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 50.26%. Additionally, its Average True Range was 0.45.
During the past 100 days, Ocular Therapeutix Inc’s (OCUL) raw stochastic average was set at 4.55%, which indicates a significant decrease from 14.41% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 42.20% in the past 14 days, which was lower than the 54.04% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.42, while its 200-day Moving Average is $8.10. However, in the short run, Ocular Therapeutix Inc’s stock first resistance to watch stands at $8.66. Second resistance stands at $9.11. The third major resistance level sits at $9.42. If the price goes on to break the first support level at $7.90, it is likely to go to the next support level at $7.59. Assuming the price breaks the second support level, the third support level stands at $7.14.
Ocular Therapeutix Inc (NASDAQ: OCUL) Key Stats
There are currently 157,217K shares outstanding in the company with a market cap of 1.29 billion. Presently, the company’s annual sales total 58,440 K according to its annual income of -80,740 K. Last quarter, the company’s sales amounted to 15,430 K and its income totaled -36,490 K.
